3 Scenarios That Would Make Aurora Cannabis (TSX:ACB) Soar Overnight

Investors have been incredibly patient with Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB), but if any of these scenarios happen, that patience could be rewarded overnight.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

There’s been one word that comes up again and again regarding cannabis stock Aurora Cannabis (TSX:ACB)(NYSE:ACB), and that word is patience.

Investors have been told a million-and-one times that they will have to wait and then wait some more to see this company come into its glory. International expansion, low-cost production, and sky-high production rates promised, investors are sitting around twiddling their thumbs while they wait for this stock to slowly rise.

And granted, it has risen. Since the drop at the end of 2018, Aurora stock has come up about 50%. Another 60% and the stock will be at its 52-week high!

Investors haven’t been hopeful of this happening, given the stock’s recent performance coupled with not only disappointing results for the company, but for its peers as well. However, there are a few scenarios where Aurora’s stock price could soar overnight.

Partnering up

Where other cannabis companies have ramped up operations with the funding of brand-name partnerships, Aurora has taken another path. The company has used shareholder cash to pay for acquisitions and expansion, and its diluted shares, leaving shareholders none too thrilled over its methods.

But the company says there is method to its madness. When they brought on billionaire Nelson Peltz as a strategic advisor, Peltz supported Aurora’s decision, seeing Aurora’s independence as beneficial to the company’s long-term success. Rather than have to make decisions based on another company’s views, Aurora can do what it wants, when it wants.

That doesn’t mean there won’t be any partnerships. In fact, Aurora has said it’s open to multiple smaller partnerships across market segments ranging from beverages to makeup. Peltz’s Rolodex will certainly be helpful for those partnerships, and any of those announcements could give the stock a major boost.

Recurring revenue

The next issue is Aurora’s need to prove it can create recurring revenue in its books. This will be a difficult task, as the company has been on a spending spree to ramp up its operations. Aurora is now the world’s second-largest marijuana producer, but even more than that, it also produces for the lowest cost. Where others are producing pot at between $3 and $7 per gram sold, Aurora is currently at around $1.50 with plans to bring that all the way down to $1 per gram.

What does this mean for investors? As soon as Aurora can prove it can bring in recurring revenue, shareholders should be thrilled knowing that as revenue grows, it won’t be eaten up by production costs. That should make Aurora a profitable company far before its peers.

To prove it can bring in that revenue, however, will be tricky. The company will need to show over at least three quarters that it can bring in recurring revenue again and again. Until then, investors will, of course, have to wait. But once that happens, confidence in the company should translate directly into the stock price.

International sales

Investors have been about two minds when it comes to Aurora’s production. On the one hand, Canadians want pot, and there is a backlog to get it. On the other, they fear Aurora might be planning to produce too much to supply Canadians with. The company has the capacity to produce about 625,000 kilograms annually, and that is set to climb to 750,000 kilograms.

But here’s the thing: Aurora isn’t thinking about just Canada. It’s not even just thinking about North America. It’s thinking global. The company already has a presence in 24 countries, looking across Europe to find where cannabis is most likely to be legalized and getting in on the ground floor. And it’s working. International medical sales recently grew by 38% to $4 million in the last earnings report.

The problem is, until Aurora can fill that Canadian craving for pot, it won’t be able to send out as much marijuana globally. Once that goal is reached, hopefully within the next two years, international sales could outpace Canadian sales, leaving Aurora in a prime position to have a continuous stream of diverse revenue from across the world. When that’s noted in its earnings report, expect stocks to soar.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe owns shares of Aurora Cannabis.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »